Treatment Outcome of Human Immunodeficiency Virus Infected Children: A Retrospective Cohort Study in a Private Hospital in Nigeria
[1]
Martha Omoo Ochoga, Department of Paediatrics, Madonna Hospital, Makurdi, Nigeria.
[2]
Onyemocho Audu, Department of Epidemiology and Community Health, Benue State University, Teaching Hospital, Makurdi, Nigeria.
[3]
Emeka U. Ejeliogu, Department of Paediatrics, Jos University Teaching Hospital, Jos, Nigeria.
[4]
Ame Idoko, Department of Paediatrics, Madonna Hospital, Makurdi, Nigeria.
[5]
Rose O. Abah, Department of Paediatrics, Benue State University Teaching Hospital, Makurdi, Nigeria.
[6]
Augustine O. Ebonyi, Department of Paediatrics, Jos University Teaching Hospital, Jos, Nigeria.
Background: The pandemic of Human Immunodeficiency Virus (HIV) and Acquired immunodeficiency syndrome (AIDS) has reversed many of the health and developmental gains over the past three decades, especially in low income countries. This study assessed the treatment outcome of HIV-infected children after two years on highly active antiretroviral therapy (HAART) in a private health facility in Benue State, North-Central Nigeria. Methodology: A retrospective study was employed to review the clinical records of HIV-infected children from January 2004 to December 2014. Data obtained was analysed with Statistical packages for social sciences (SPSS) version 20.0. Chi-square (χ2) test was used for test of association between the independent variables and the main outcomes of the study, with P value set at 0.05. Results: One hundred and one children were initiated on HAART within the period. The mean age of the patients was 8.5±3.0 years. Majority (43.6%) of those initiated on HAART had World Health Organization (WHO) clinical stage 2 disease while 63.4% were on cotrimoxazole prophylaxis. Ten (9.9%) were lost to follow up, 4.0% were transferred to a tertiary health facility while 2.0% died. Overall patients with baseline CD4 count of >350 cell/mm3 and those with WHO stages 1 and 2 disease had higher rates of survival after two years on HAART. Conclusion: With prompt access to Antiretroviral Therapy (ART0 majority of HIV-1 infected children diagnosed early can now reach adulthood.
Paediatrics, HIV, ART, Outcome, Private Hospital, Nigeria
[1]
UNAIDS. Regional fact sheet 2012:Sub-Saharan Africa. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/2012-FS-regional-ssa-en.pdf [Last acceded on 2015 Apr 30].
[2]
UNAIDS. UNAIDS AIDS report on Global AIDS epidemic 2013.Availablefrom: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf [Last accessed on 2014 Dec 30].
[3]
Global Health Facts. Children living with HIV/AIDS <15 years old 2011. Available from http//www.globalhealthfacts.org/data/topic/map.aspx?ind=6. [Last accessed on 2014 Apr 27].
[4]
Vreeman RC, Wiche SE, Pearce EC, Nyandiko WM.A systematic review of pediatric adherence to antiretroviral therapy in low income countries. Pediatr Infect Dis J2008;27:686-691.
[5]
Biadgilign S, Deribew A, Amberbir A, Deribe K.Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethopia. BMC Pediatr 2008;8:53-18
[6]
Haberer J, Mellins C. Pediatric Adherence to HIV Antiretroviral Therapy. Curr HIV/AIDS Rep 2009;6:194-200.
[7]
WHO. Adherence to long-term therapies: Evidence for action. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf[last accessed on 2014 Mar 20].
[8]
Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: A qualitative study. SAHARA J 2009;6:148-54.
[9]
AO Ebonyi, S Oguche, E Dablets, B Sumi, E Yakubu, AS Sagay. Effect of HAART on growth parameters and absolute parameters and absolute CD4 count among HIV-infected children in a rural community of central Nigeria. Niger J Paed 2014;41(1):1-6.
[10]
Federal Ministry of Health, Nigeria: National Guidelines for Paediatric HIV and AIDS Treatment and Care; 2010.
[11]
Johann-Liang R, Cervia JS, Noel GJ. Characteristics of human immunodeficiency virus-infected children at the time of death: an experience in the 1990s. Pediatr Infect Dis J. 1997;16:1145–1150. [PubMed]
[12]
Langston C, Cooper ER, Goldfarb J, et al. Human immunodeficiency virus related mortality in infants and children: data from the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV (P2C2) study. Pediatrics. 2001;107:328–338. [PMC free article] [PubMed]
[13]
Chiappini E, Galli L, Tovo P-A, et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS. 2007;21:1607–1615. [PubMed]
[14]
Doerholt K, Duong T, Tookey P, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25:420–426. [PubMed]
[15]
Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F, Rouzioux C, Blanche S. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. J Med Virol. 2007;79:1261–1269. [PubMed]
[16]
Barry G, Coovadia A, Marais B, Malan E, Moultrie H. Analysis of HIV-infected infants under 1 year starting antiretroviral treatment at Coronation Paediatric HIV Clinic in Coronationville, Johannesburg [abstract MoPe0233]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada
[17]
Anabwani GM, Lowenthal E, Marape M. et al. Long term response to highly active antiretroviral therapy among treatment naive children in Botswana [abstract MoPe0261]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada
[18]
Olson D, Sauvageot D, Ferradini L, Humblet P. Antiretroviral therapy (ART) outcomes in children <13 years of age in resource-poor countries (RPCs): a medecins sans frontieres (MSF) cohort [abstract MoAb0204]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada
